



ABOUT HYBRIGENICS

Founded as the first spin-off of the Pasteur Institute in 1997 and located in Paris, France, Hybrigenics is discovering and developing innovative drug candidates with a focus on oncology. Development drug inecalcitol, a vitamin D analogue, is currently in phase II clinical trial for the treatment of hormone resistant prostate cancer, an area of unmet medical need.

Hybrigenics' research is targeting and validating the ubiquitin-specific proteases (USPs) that are prominently involved in cancer cell proliferation. Lead USP inhibitor HBX 99,200 is currently undergoing in vivo testing in collaboration with the National Cancer Institute (Bethesda, USA).

Besides its Pharma R&D activities, Hybrigenics provides access to its functional technology platform on a fee-for-service basis: its 'Yeast Two-Hybrid platform' is the most thorough and sensitive technology to detect and identify proteins that interact with any selected protein in a given organism, tissue or cell type.

Hybrigenics has raised € 47 million from venture capital funds to date.

ABOUT INECALCITOL

Inecalcitol belongs to the class of vitamin D analogues, a mature pharmaceutical class known for its efficacy in several indications. Vitamin D analogues are now recognized for their potent role in cell proliferation and cell differentiation making them promising drug candidates for the treatment of cancer patients. Inecalcitol is a synthetic derivative of calcitriol, the natural active metabolite of vitamin D3. Inecalcitol, however is ten times more potent and one hundred times less toxic than calcitriol. This profile positions inecalcitol as an effective drug candidate, initially for the treatment of hormone-resistant prostate cancer.

Hybrigenics has acquired a license for the worldwide exclusive rights to inecalcitol for all therapeutic indications.

INECALCITOL

ADDRESSING UNMET MEDICAL NEEDS IN PROSTATE CANCER WITH INECALCITOL


Prostate cancer has become the leading reported case of cancer and the second leading cause of cancer deaths in men in the United States. Prostate cancer is the third most common cancer worldwide with more than 670,000 new cases each year.

In 2005, close to 395,000 patients were treated for prostate cancer in the G7 countries. According to the American Cancer Society 234,460 new cases of prostate cancer were reported in 2006 in the US alone, with an estimated 27,350 deaths. In 2005 drug revenues for the treatment of prostate cancer exceeded 3 billion US\$ and is estimated to grow to over 7 billion US\$ by 2012.

Prostate cancer is a chronic disease of men almost exclusively over 50 years old, evolving in two phases. Initially, most prostate cancers depend on male hormones for their sustained growth and anti-hormonal therapies are very effective in stabilizing hormone-dependent prostate cancer for several months or years. Inevitably however, tumor progression resumes despite anti-hormonal treatment, and the prostate cancer is then defined as hormone-refractory. This transition is called hormonal escape.

The prognosis for hormone-refractory prostate cancer patients is poor. Their treatment option is presently limited to chemotherapy with docetaxel (Taxotere from Sanofi-Pasteur) as the accepted standard-of-care. The median survival expectancy for these patients does not exceed 19 months. Hormone-refractory prostate cancer affects approximately 220,000 patients in the 7 major pharma markets of which 60,000 new cases are reported each year in the US alone.

Aimed at addressing this medical need, Hybrigenics' inecalcitol is in phase II clinical trial for the treatment of hormone-refractory prostate cancer in combination with Taxotere; the chemotherapy of choice.



HYBRIGENICS KEY FACTS :

- > Founded in 1997 and based in Paris, France.
- > Focused on discovery and development of novel oncology drug candidates.
- > Research program on inhibitors of Ubiquitin-Specific Proteases in cancer.
- > Development drug inecalcitol in clinical phase II as treatment for patients diagnosed with hormone-refractory prostate cancer.
- > Worldwide rights on inecalcitol for all clinical indications.
- > Fee-for-service activities in identification, validation and inhibition of protein-protein interaction.
- > 44 employees.

STATUS INECALCITOL CANCER DRUG DEVELOPMENT

Hybrigenics' drug candidate is an oral formulation of inecalcitol in cancer indications, initially as first line treatment for hormone-refractory prostate cancer in combination with docetaxel (Taxotere) chemotherapy.

Pre-clinical and clinical study results show that inecalcitol is well tolerated orally, that no adverse events have been reported, and that no modification of blood calcium and urinary calcium levels are measured after a single dose administration of up to 320 micrograms. The primary endpoint of this development program, in combination with the administration of docetaxel (Taxotere) is an improvement of overall survival rate. The clinical phase II dose escalating study of inecalcitol in patients with hormone-refractory prostate cancer has been approved by the French regulatory authorities, and patients will commence treatment in the fourth quarter of 2007. The objective of the phase II study is to determine the maximum tolerated dose as a basis for the scheduled phase III efficacy trial.

THE FUTURE OF INECALCITOL

The pre-clinical profile of inecalcitol, in combination with the clinical data generated to date, underlines Hybrigenics' strategy to proceed to demonstrate the efficacy of inecalcitol in hormone-refractory prostate cancer patients. Hybrigenics plans to market inecalcitol worldwide with a partner in this indication.

In parallel, Hybrigenics is in the process of evaluating the use of inecalcitol in hormone-dependent prostate cancer in combination with standard anti-hormonal therapies, with the aim of extending the remission period before hormonal escape. Furthermore, given its potent general anti-proliferative and pro-differentiating properties on several cancer cell lines, the potential indications of inecalcitol could be extended to other cancers in the future.

CONTACT US

Hybrigenics is pro-active in establishing contacts and research & development collaborations with biotech and pharmaceutical companies. Hybrigenics is open to different collaboration structures wherever there is potential for a good strategic fit.

To discuss business development ideas or to explore potential collaboration you are invited to contact Hybrigenics:

Mr. Kees Moonen
Business Development
Hybrigenics

Phone +31 (0) 655 852 612
Email : kmoonen@hybrigenics.com
www.hybrigenics.com

